Q/C Technologies, Inc.
QCLS- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001321834
No open-market purchases or sales by Q/C Technologies, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $2.87M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $2.83M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +4 vs. previous quarter
- 21
- 13F valueReported value at the end of Q2 2026
- $2.87M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$11.6M
- No comparable prior period
- Free cash flow, FY2025
- -$10.8M
- No comparable prior period
- Revenue, Q2 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 908.3K
- Shares sold short
- Change
- −89.1K
- −8.9% vs. previous
- Days to cover
- 6.16
- At average daily volume
Superinvestors holding QCLS, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding QCLS at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Q/C Technologies, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 14, 2026 (view filing) | Mar 30 | 45 daysLate | Voss Chelsea SierraDirector | PPurchase | +1.75K | $3.15 | +$5.52K | +2.9%61.6K after | |
| Nov 18, 2025 (view filing) | Sep 4-Nov 14 | 75 daysLate | PharmaCyte Biotech, Inc.10% Owner | PPurchaseCommon stock, par value $0.001 per share | +1.78M | – | – | –889.9K after | Derivative2 lots |
| Aug 24, 2023 (view filing) | Aug 24 | Same day | Rivard PaulChief Legal Officer | PPurchase | +150.0K | $1.11 | +$166.5K | +60.0%400.0K after | |
| Aug 18, 2023 (view filing) | Aug 17 | 1 day | Rivard PaulChief Legal Officer | PPurchase | +25.0K | $1.12 | +$28.0K | +11.1%250.0K after | |
| Dec 8, 2022 (view filing) | Dec 8 | Same day | Rivard PaulEVP of Operations, GC | PPurchase | +10.0K | $1.53 | +$15.3K | +4.7%225.0K after | |
| Nov 29, 2021 (view filing) | Nov 24-26 | 5 days | Silverman JoshuaDirector | PPurchase | +15.0K | $6.89 | +$103.3K | +20.3%88.8K after | 3 lots |
| Nov 24, 2021 (view filing) | Nov 23 | 1 day | Rivard PaulEVP of Operations, GC | PPurchase | +15.0K | $6.03 | +$90.5K | +7.5%215.0K after |
Top 10 13F holders, Q2 2026
See all 21 holdersThe largest institutional positions in Q/C Technologies, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Quinn Opportunity Partners LLC | 123,024 | $479.8K | 0.02% | −88,366−41.8% | Reduced |
| Vanguard Capital Management LLC | 115,031 | $448.6K | 0.00% | +77,520+206.7% | Added |
| Jane Street Group, LLC | 87,241 | $340.2K | 0.00% | −38,947−30.9% | Reduced |
| Geode Capital Management, LLC | 70,682 | $275.7K | 0.00% | +23,292+49.1% | Added |
| UBS Group AG | 58,894 | $229.7K | 0.00% | −19,095−24.5% | Reduced |
| Balyasny Asset Management LLC | 57,692 | $225.0K | 0.00% | +57,692 | New |
| HRT Financial LP | 50,373 | $196.0K | 0.00% | +27,969+124.8% | Added |
| ADAR1 Capital Management, LLC | 50,000 | $195.0K | 0.01% | 00.0% | Unchanged |
| Vanguard Fiduciary Trust Co | 43,053 | $167.9K | 0.00% | +27,498+176.8% | Added |
| State Street Corp | 25,305 | $98.7K | 0.00% | +12,400+96.1% | Added |
Holders of 5% or more of QCLS
See all 1 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Q/C Technologies, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| PharmaCyte Biotech, Inc. | 13D/A | 74.00%8.48M shares | – | May 30, 20242 filings | Nov 18, 2025 | SEC |